Evidence map›Paper›PMID 34729106›Full record

ArticleJournal of Cancer2021

N6-methyladenosine regulates ATM expression and downstream signaling.

Xiaoyue Zhang, Peishan Liu, Xiang Zheng, Jia Wang, Qiu Peng, Zhengshuo Li, Lingyu Wei, Can Liu, Yangge Wu, Yuqing Wen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Filgotinib inhibits METTL3-mediated mNPJ precision oncology · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. The crosstalk of mTrends in biochemical sciences · 2025
    Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Xiaoyue ZhangHunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Peishan LiuCancer Research Institute and School of Basic Medical Science, Central South University, Changsha, China.
Xiang ZhengCancer Research Institute and School of Basic Medical Science, Central South University, Changsha, China.
Jia WangCancer Research Institute and School of Basic Medical Science, Central South University, Changsha, China.
Qiu PengHunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Zhengshuo LiCancer Research Institute and School of Basic Medical Science, Central South University, Changsha, China.
Lingyu WeiCancer Research Institute and School of Basic Medical Science, Central South University, Changsha, China.
Can LiuCancer Research Institute and School of Basic Medical Science, Central South University, Changsha, China.
Yangge WuCancer Research Institute and School of Basic Medical Science, Central South University, Changsha, China.
Yuqing WenCancer Research Institute and School of Basic Medical Science, Central South University, Changsha, China.
Qun YanDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, China.
Jian MaHunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Central South University · CNHunan Cancer Hospital · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

N6-methyladenosine (m6A) is the most abundant modification in eukaryotic mRNAs, which plays an important role in regulating multiple biological processes. ATM is a major protein kinase that regulates the DNA damage response. Here, we identified that

Indexed as

ATMDNA damage responsem6A modificationMETTL3YTHDF1

Identifiers

PMID34729106
PMCPMC8558655
OpenAlexW3208713490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.